Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 37 studies | 47% ± 21% | |
fibroblast | 32 studies | 32% ± 16% | |
endothelial cell | 29 studies | 35% ± 18% | |
macrophage | 23 studies | 33% ± 16% | |
smooth muscle cell | 23 studies | 33% ± 14% | |
classical monocyte | 18 studies | 31% ± 13% | |
B cell | 15 studies | 28% ± 10% | |
monocyte | 14 studies | 34% ± 16% | |
non-classical monocyte | 13 studies | 30% ± 14% | |
astrocyte | 12 studies | 35% ± 17% | |
conventional dendritic cell | 12 studies | 29% ± 17% | |
microglial cell | 12 studies | 48% ± 19% | |
myeloid cell | 12 studies | 33% ± 13% | |
adipocyte | 11 studies | 60% ± 16% | |
dendritic cell | 10 studies | 44% ± 16% | |
basal cell | 10 studies | 36% ± 16% | |
neutrophil | 9 studies | 30% ± 11% | |
GABAergic neuron | 9 studies | 40% ± 21% | |
glutamatergic neuron | 9 studies | 48% ± 21% | |
oligodendrocyte precursor cell | 9 studies | 35% ± 18% | |
natural killer cell | 8 studies | 22% ± 6% | |
connective tissue cell | 8 studies | 25% ± 8% | |
neuron | 8 studies | 40% ± 18% | |
epithelial cell | 8 studies | 41% ± 17% | |
ciliated cell | 8 studies | 31% ± 9% | |
oligodendrocyte | 7 studies | 33% ± 10% | |
T cell | 6 studies | 26% ± 8% | |
CD4-positive, alpha-beta T cell | 6 studies | 23% ± 8% | |
retina horizontal cell | 6 studies | 28% ± 13% | |
myofibroblast cell | 6 studies | 32% ± 13% | |
type I pneumocyte | 6 studies | 28% ± 9% | |
type II pneumocyte | 6 studies | 34% ± 10% | |
plasmacytoid dendritic cell | 6 studies | 20% ± 5% | |
naive B cell | 5 studies | 21% ± 5% | |
mononuclear phagocyte | 5 studies | 45% ± 6% | |
CD8-positive, alpha-beta T cell | 5 studies | 21% ± 4% | |
retinal bipolar neuron | 5 studies | 37% ± 14% | |
glial cell | 5 studies | 34% ± 16% | |
interneuron | 5 studies | 58% ± 23% | |
club cell | 5 studies | 33% ± 11% | |
amacrine cell | 5 studies | 36% ± 17% | |
retinal cone cell | 5 studies | 28% ± 10% | |
cardiac muscle cell | 5 studies | 27% ± 6% | |
Mueller cell | 5 studies | 39% ± 20% | |
endothelial cell of lymphatic vessel | 5 studies | 31% ± 9% | |
goblet cell | 5 studies | 32% ± 22% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 21% ± 4% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 23% ± 2% | |
effector memory CD8-positive, alpha-beta T cell | 4 studies | 23% ± 6% | |
hematopoietic precursor cell | 4 studies | 39% ± 17% | |
granule cell | 4 studies | 44% ± 16% | |
retinal ganglion cell | 4 studies | 30% ± 14% | |
immature B cell | 4 studies | 33% ± 14% | |
retinal pigment epithelial cell | 4 studies | 40% ± 22% | |
endothelial cell of artery | 4 studies | 19% ± 1% | |
mast cell | 4 studies | 28% ± 10% | |
vein endothelial cell | 4 studies | 27% ± 13% | |
retinal rod cell | 4 studies | 26% ± 6% | |
endothelial cell of vascular tree | 4 studies | 34% ± 15% | |
hepatocyte | 4 studies | 60% ± 16% | |
muscle cell | 4 studies | 39% ± 18% | |
leukocyte | 4 studies | 32% ± 6% | |
regulatory T cell | 4 studies | 17% ± 1% | |
melanocyte | 4 studies | 54% ± 24% | |
hepatic stellate cell | 3 studies | 58% ± 13% | |
mature NK T cell | 3 studies | 24% ± 9% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 25% ± 5% | |
plasma cell | 3 studies | 33% ± 9% | |
brush cell | 3 studies | 24% ± 9% | |
precursor B cell | 3 studies | 37% ± 14% | |
pro-B cell | 3 studies | 34% ± 12% | |
mesothelial cell | 3 studies | 39% ± 12% | |
lymphocyte | 3 studies | 36% ± 7% | |
GABAergic amacrine cell | 3 studies | 42% ± 14% | |
OFF-bipolar cell | 3 studies | 61% ± 18% | |
ON-bipolar cell | 3 studies | 52% ± 13% | |
glycinergic amacrine cell | 3 studies | 42% ± 9% | |
rod bipolar cell | 3 studies | 53% ± 13% | |
memory B cell | 3 studies | 23% ± 10% | |
enteroendocrine cell | 3 studies | 22% ± 7% | |
alveolar macrophage | 3 studies | 40% ± 9% | |
capillary endothelial cell | 3 studies | 31% ± 14% | |
chondrocyte | 3 studies | 34% ± 4% | |
respiratory goblet cell | 3 studies | 35% ± 14% | |
Schwann cell | 3 studies | 53% ± 21% | |
transit amplifying cell | 3 studies | 34% ± 24% | |
mucus secreting cell | 3 studies | 28% ± 7% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 13 studies | 38% ± 18% | |
lung | 11 studies | 29% ± 9% | |
eye | 8 studies | 34% ± 16% | |
peripheral blood | 6 studies | 33% ± 16% | |
intestine | 5 studies | 25% ± 8% | |
heart | 5 studies | 32% ± 7% | |
liver | 4 studies | 36% ± 13% | |
adipose | 4 studies | 40% ± 21% | |
placenta | 3 studies | 23% ± 9% | |
uterus | 3 studies | 29% ± 9% | |
bone marrow | 3 studies | 29% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6237.96 | 1445 / 1445 | 100% | 32.79 | 183 / 183 |
thymus | 100% | 7510.79 | 653 / 653 | 100% | 34.64 | 603 / 605 |
breast | 100% | 11007.84 | 459 / 459 | 99% | 36.41 | 1111 / 1118 |
brain | 99% | 5196.92 | 2628 / 2642 | 100% | 23.36 | 704 / 705 |
kidney | 100% | 5061.43 | 89 / 89 | 99% | 30.00 | 891 / 901 |
pancreas | 99% | 4071.44 | 324 / 328 | 100% | 34.54 | 178 / 178 |
lung | 100% | 7918.86 | 578 / 578 | 99% | 25.77 | 1138 / 1155 |
intestine | 100% | 6908.17 | 966 / 966 | 98% | 22.69 | 519 / 527 |
bladder | 100% | 7341.05 | 21 / 21 | 98% | 22.59 | 495 / 504 |
stomach | 100% | 4967.98 | 359 / 359 | 98% | 26.69 | 279 / 286 |
ovary | 100% | 7367.52 | 180 / 180 | 97% | 26.23 | 419 / 430 |
adrenal gland | 100% | 6094.11 | 258 / 258 | 97% | 26.18 | 224 / 230 |
liver | 100% | 4249.85 | 226 / 226 | 97% | 18.94 | 395 / 406 |
prostate | 100% | 7392.93 | 245 / 245 | 97% | 25.78 | 488 / 502 |
uterus | 100% | 10229.56 | 170 / 170 | 97% | 26.34 | 446 / 459 |
skin | 100% | 5909.53 | 1809 / 1809 | 92% | 23.65 | 433 / 472 |
adipose | 100% | 13270.10 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 9260.84 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.66 | 29 / 29 |
spleen | 100% | 9848.62 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 18.28 | 1 / 1 |
peripheral blood | 100% | 15476.31 | 927 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 34.06 | 79 / 80 |
heart | 98% | 4262.85 | 848 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 24.95 | 44 / 45 |
muscle | 96% | 3483.79 | 770 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0048870 | Biological process | cell motility |
GO_0021955 | Biological process | central nervous system neuron axonogenesis |
GO_2000773 | Biological process | negative regulation of cellular senescence |
GO_0032286 | Biological process | central nervous system myelin maintenance |
GO_0051895 | Biological process | negative regulation of focal adhesion assembly |
GO_2000463 | Biological process | positive regulation of excitatory postsynaptic potential |
GO_1904668 | Biological process | positive regulation of ubiquitin protein ligase activity |
GO_0001933 | Biological process | negative regulation of protein phosphorylation |
GO_2000060 | Biological process | positive regulation of ubiquitin-dependent protein catabolic process |
GO_0033555 | Biological process | multicellular organismal response to stress |
GO_0050821 | Biological process | protein stabilization |
GO_0090394 | Biological process | negative regulation of excitatory postsynaptic potential |
GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0071257 | Biological process | cellular response to electrical stimulus |
GO_0007417 | Biological process | central nervous system development |
GO_0030534 | Biological process | adult behavior |
GO_0033137 | Biological process | negative regulation of peptidyl-serine phosphorylation |
GO_0035176 | Biological process | social behavior |
GO_0045792 | Biological process | negative regulation of cell size |
GO_0007626 | Biological process | locomotory behavior |
GO_0048853 | Biological process | forebrain morphogenesis |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0006470 | Biological process | protein dephosphorylation |
GO_0045475 | Biological process | locomotor rhythm |
GO_0046621 | Biological process | negative regulation of organ growth |
GO_0060024 | Biological process | rhythmic synaptic transmission |
GO_0010975 | Biological process | regulation of neuron projection development |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0045736 | Biological process | negative regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0097105 | Biological process | presynaptic membrane assembly |
GO_0006661 | Biological process | phosphatidylinositol biosynthetic process |
GO_0097107 | Biological process | postsynaptic density assembly |
GO_0051896 | Biological process | regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0021542 | Biological process | dentate gyrus development |
GO_0046856 | Biological process | phosphatidylinositol dephosphorylation |
GO_0051548 | Biological process | negative regulation of keratinocyte migration |
GO_0010977 | Biological process | negative regulation of neuron projection development |
GO_0007056 | Biological process | spindle assembly involved in female meiosis |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0007416 | Biological process | synapse assembly |
GO_0016477 | Biological process | cell migration |
GO_1903690 | Biological process | negative regulation of wound healing, spreading of epidermal cells |
GO_1902807 | Biological process | negative regulation of cell cycle G1/S phase transition |
GO_1904706 | Biological process | negative regulation of vascular associated smooth muscle cell proliferation |
GO_0007507 | Biological process | heart development |
GO_0007611 | Biological process | learning or memory |
GO_0050771 | Biological process | negative regulation of axonogenesis |
GO_0007270 | Biological process | neuron-neuron synaptic transmission |
GO_0060070 | Biological process | canonical Wnt signaling pathway |
GO_0051898 | Biological process | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0042711 | Biological process | maternal behavior |
GO_0010719 | Biological process | negative regulation of epithelial to mesenchymal transition |
GO_0060074 | Biological process | synapse maturation |
GO_0006915 | Biological process | apoptotic process |
GO_2000134 | Biological process | negative regulation of G1/S transition of mitotic cell cycle |
GO_2000808 | Biological process | negative regulation of synaptic vesicle clustering |
GO_0060134 | Biological process | prepulse inhibition |
GO_0031647 | Biological process | regulation of protein stability |
GO_0060997 | Biological process | dendritic spine morphogenesis |
GO_0043005 | Cellular component | neuron projection |
GO_0016605 | Cellular component | PML body |
GO_0035749 | Cellular component | myelin sheath adaxonal region |
GO_0005634 | Cellular component | nucleus |
GO_0005576 | Cellular component | extracellular region |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005886 | Cellular component | plasma membrane |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0014069 | Cellular component | postsynaptic density |
GO_0005737 | Cellular component | cytoplasm |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0043197 | Cellular component | dendritic spine |
GO_0043220 | Cellular component | Schmidt-Lanterman incisure |
GO_0005829 | Cellular component | cytosol |
GO_0042995 | Cellular component | cell projection |
GO_0051717 | Molecular function | inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity |
GO_0052866 | Molecular function | phosphatidylinositol phosphate phosphatase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0016314 | Molecular function | phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity |
GO_0051800 | Molecular function | phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity |
GO_1990381 | Molecular function | ubiquitin-specific protease binding |
GO_0004438 | Molecular function | phosphatidylinositol-3-phosphate phosphatase activity |
GO_0004721 | Molecular function | phosphoprotein phosphatase activity |
GO_0017018 | Molecular function | myosin phosphatase activity |
GO_1990757 | Molecular function | ubiquitin ligase activator activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0030351 | Molecular function | inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity |
GO_0008289 | Molecular function | lipid binding |
GO_0030165 | Molecular function | PDZ domain binding |
GO_0005515 | Molecular function | protein binding |
GO_0004722 | Molecular function | protein serine/threonine phosphatase activity |
GO_0010997 | Molecular function | anaphase-promoting complex binding |
GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
Gene name | PTEN |
Protein name | Mitochondrial PTENalpha Phosphatase and tensin-like protein Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (EC 3.1.3.16) (EC 3.1.3.48) (EC 3.1.3.67) (Inositol polyphosphate 3-phosphatase) (EC 3.1.3.-) (Mutated in multiple advanced cancers 1) (Phosphatase and tensin homolog) Phosphatase and tensin-like protein mutant variant 3 PTENbeta (EC 3.1.3.67) Phosphatase and tensin homolog Phosphatase and tensin-like protein (Phosphatase and tensin-like protein mutant variant 2) (Phosphatase and tensin-like protein mutant variant 4) (Phosphatase and tensin-like protein mutant variant 5) protein-serine/threonine phosphatase (EC 3.1.3.16) Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (EC 3.1.3.16) (EC 3.1.3.48) (EC 3.1.3.67) (Phosphatase and tensin homolog) Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (EC 3.1.3.67) |
Synonyms | hCG_1737352 MMAC1 TEP1 |
Description | FUNCTION: Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3. . FUNCTION: Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3. . FUNCTION: Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3. . FUNCTION: Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins . Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3 . Furthermore, this enzyme can also act as a cytosolic inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5-tetrakisphosphate . Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival . The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation . In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement . Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation . Required for growth factor-induced epithelial cell migration; growth factor stimulation induces PTEN phosphorylation which changes its binding preference from the p85 regulatory subunit of the PI3K kinase complex to DLC1 and results in translocation of the PTEN-DLC1 complex to the posterior of migrating cells to promote RHOA activation . Meanwhile, TNS3 switches binding preference from DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge of migrating cells to activate RAC1 activation . Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Involved in the regulation of synaptic function in excitatory hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA receptor activation, is required for the modulation of synaptic activity during plasticity. Enhancement of lipid phosphatase activity is able to drive depression of AMPA receptor-mediated synaptic responses, activity required for NMDA receptor-dependent long-term depression (LTD) (By similarity). May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability . .; FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1. . FUNCTION: Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3. . |
Accessions | ENST00000710265.1 A0A2P0XNP6 A0A386NCS8 A0A087X033 ENST00000710387.1 [P60484-2] A0AA34QVZ8 A0A2R4SE35 A0A142FGX1 A0A8I5KSF9 ENST00000700021.1 A0A8V8TPK6 A0A386NBZ2 ENST00000700029.2 ENST00000706955.1 H6WA52 ENST00000371953.8 [P60484-1] A0A024QYR6 A0A8V8TQX2 A0A1V0DNR7 A0A8V8TP77 ENST00000688308.1 [P60484-1] ENST00000688922.2 H6WA46 A0A9L9PYJ2 F6KD01 ENST00000693560.1 A0A8I5KR36 ENST00000686459.1 P60484 H6WA51 ENST00000644628.2 [P60484-1] ENST00000710385.1 [P60484-1] ENST00000700022.1 A0A8I5KVQ8 ENST00000472832.3 |